Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Zymeworks is a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics using proprietary platforms including Azymetric (bispecific antibodies) and EFECT (antibody-drug conjugates). The company has transitioned from a platform licensing model to a clinical development focus, with lead asset zanidatamab (HER2-targeted bispecific) in Phase 3 trials for biliary tract cancer and gastroesophageal adenocarcinoma, plus a pipeline of ADCs targeting solid tumors.
Zymeworks operates a dual model: (1) near-term revenue from platform licensing deals and research collaborations with pharma partners who pay upfront fees, milestones, and royalties; (2) long-term value creation through wholly-owned clinical programs, particularly zanidatamab which could generate product sales if approved. The company's Azymetric platform enables differentiated bispecific antibodies with improved manufacturability versus competitors, while EFECT technology creates next-generation ADCs. Current cash burn of ~$100M annually supports multiple clinical trials, with regulatory catalysts expected through 2026-2027 for lead programs.
Zanidatamab clinical trial readouts (Phase 3 HERIZON-BTC-01 in biliary tract cancer, Phase 2b HERIZON-GEA-01 in gastric/GEJ cancer)
FDA regulatory milestone progress and potential accelerated approval pathways for zanidatamab
Pipeline advancement announcements for ZW171 (2B4xCD3 bispecific) and ZW251 (HER2 ADC) programs
Strategic partnership announcements or licensing deals that validate platform technology and provide non-dilutive funding
Cash runway updates and financing activities (equity raises, debt facilities) given ongoing burn rate
Clinical trial failure risk for zanidatamab in Phase 3 studies, which would eliminate near-term path to commercialization and require pipeline pivot
Competitive intensity in HER2-targeted therapeutics with established players (Enhertu, Kadcyla) and emerging bispecifics creating high efficacy/safety bars for differentiation
Regulatory approval uncertainty for novel bispecific and ADC modalities, particularly regarding manufacturing complexity and immunogenicity concerns
Platform technology commoditization risk as bispecific antibody capabilities become more widespread across industry
Daiichi Sankyo/AstraZeneca's Enhertu dominance in HER2+ cancers with strong clinical data creating difficult competitive positioning for zanidatamab
Large pharma internal bispecific programs (Roche, Amgen, Regeneron) reducing demand for external platform licensing
Emerging ADC competitors with differentiated linker-payload technologies potentially superior to EFECT platform
Cash runway risk requiring additional financing within 24-36 months at current $100M+ annual burn rate, with dilution risk if raised at unfavorable valuations
Minimal revenue generation ($10M TTM) provides no self-funding capability, creating total dependence on capital markets or partnerships
Potential need for dilutive financing if clinical setbacks extend timelines or require additional trials before commercialization
low - Pre-revenue clinical-stage biotech with minimal direct GDP sensitivity. Cancer drug demand is non-discretionary and insulated from economic cycles. However, capital markets conditions affect ability to raise funding, and economic downturns can impact pharma partners' willingness to pursue licensing deals or acquisitions.
Rising rates negatively impact valuation through higher discount rates applied to distant future cash flows (zanidatamab revenue potentially 2027+). Clinical-stage biotechs trade at high P/S multiples (12.8x on minimal revenue) making them sensitive to risk-free rate changes. Higher rates also increase opportunity cost of capital for speculative growth investments. Minimal direct business impact as company has low debt (0.06 D/E) and holds cash in short-term instruments that benefit from higher yields.
Minimal direct credit exposure. Strong balance sheet with 6.94x current ratio and $300M+ cash provides multi-year runway. Company may access credit facilities or convertible debt for non-dilutive financing, where tighter credit conditions could increase borrowing costs or reduce availability. Broader biotech sector funding environment affects M&A valuations and partnership economics.
growth - High-risk, high-reward clinical-stage biotech attracts speculative growth investors betting on binary clinical trial outcomes and potential acquisition by large pharma. 57% one-year return reflects momentum following positive clinical updates. Institutional biotech specialists and hedge funds with event-driven strategies dominate ownership. Not suitable for value or income investors given negative earnings, no dividends, and uncertain commercialization timeline.
high - Clinical-stage biotech with binary event risk (trial readouts, FDA decisions) creates extreme volatility. Small market cap ($1.7B) and low trading liquidity amplify price swings. Recent 60% six-month gain followed by -3.5% three-month decline illustrates event-driven volatility pattern. Expect 30-50% intraday moves on material clinical announcements.
